About The Retatrutide Report

retatrutide.us.com is an independent editorial site covering the investigational drug retatrutide (LY3437943), Eli Lilly's triple-agonist weight-loss candidate. We are not affiliated with Eli Lilly or any pharmaceutical company.

What we do

We track clinical-trial data, dosing, FDA approval progress, and competing drugs in the obesity/metabolic space. We translate dense pharmacology into plain-English explanations for a non-specialist audience. We link to primary sources (NEJM, ClinicalTrials.gov, FDA) wherever possible.

Editorial standards

Primary sources. Numbers cited on this site trace to peer-reviewed journals (NEJM, JAMA, Lancet), ClinicalTrials.gov registrations, or FDA documents. We link directly where possible.
Conservative claims. We do not project Phase 3 results from Phase 2 data without caveating the uncertainty. Retatrutide is investigational; efficacy and safety claims reference trial arms and conditions.
No vendor endorsement. We do not link, name favorably, or recommend research-peptide vendors. We view the research-peptide market as high-risk for patients and do not want to funnel traffic to it.
No medical advice. Everything on this site is educational. Medication decisions should involve a qualified healthcare provider.

Our position on research peptides

We receive a large volume of traffic from people searching "retatrutide peptide buy," "retatrutide for sale," and similar queries. We've written about this market honestly — including the risks, pricing, and quality issues — but we do not recommend research peptides for human use. When supervised FDA-approved alternatives cost roughly the same, we think the supervised path is better for most people.

Affiliate disclosure

This site contains affiliate links to licensed telehealth providers who prescribe FDA-approved GLP-1 medications. We may earn a commission when readers enroll through these links. This does not affect our editorial content — our recommendation of supervised telehealth over research peptides is based on risk and quality differences, not commission rates.

Updates and corrections

Clinical trials update quarterly; regulatory milestones shift; pricing changes. We update pages monthly at minimum, more frequently when new data is announced. If you spot an error, the site footer includes our contact.

Not a substitute for medical care

Retatrutide.us.com is an informational resource. It is not, and is not intended to be, a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician before making medication decisions.